Sign in:
Email
 Password  save:
  
 Company Reports 
 
   
My Recent Searches
  Help
 
   
 
 
Get Insiders for : 
Biomarin Pharmaceutical Inc (BMRN)    
$85.45 2.35 (2.83%) as of 4:30 Tue 11/18


Download
   
Exchange: Nasdaq National Market
Security Type: Common
Shares Out: 148,000,000 as of 9/30
Market Cap: 12.65(B)
Last Volume: 847,520 Avg Vol: 1,238,746
52 Week Range: $56.17 - $87.92
Level I Sector: Health Care
Level II Sector:   Drugs
Level III Sector:      Drug Manufacturers - Other

Member Indexes:

    NASDAQ BIOTECHNOLOGY       NASDAQ COMPOSITE  
    NASDAQ NNM COMPOSITE  

Rankings:

     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  -
Guru Rank Value     :  -
Guru Occurances    :  -

 

            6 Months   1 Year   2 Year  
 
 

Company Profile   BioMarin Pharmaceutical develops and commercializes pharmaceuticals. Co.'s approved products include: Naglazyme (galsulfase) for patients with mucopolysaccharidosis VI; Kuvan (sapropterin dihydrochloride) for the treatment of phenylketonuria; Aldurazyme (laronidase) for patients with mucopolysaccharidosis I; and Firdapse (amifampridine phosphate) for the treatment of Lambert Eaton Myasthenic Syndrome. Co. is also conducting clinical trials on several investigational product candidates including, among others: Vimizim™, for the treatment of mucopolysaccharidosis Type IV or Morquio Syndrome Type A; and PEG-PAL for the treatment of phenylketonuria.

 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 0
Total Buy Value $0 $0 $0 $0
Total People Bought 0 0 0 0
Total Buy Transactions 0 0 0 0
Total Shares Sold 156,008 177,843 369,061 1,084,973
Total Sell Value $12,453,717 $13,878,226 $27,507,773 $71,385,603
Total People Sold 6 6 9 13
Total Sell Transactions 12 19 46 136
End Date 2014-08-24 2014-05-23 2013-11-22 2012-11-22

   
Records found: 1276
  Page 1 of 52  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

 
3m +/-  
Form
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2014-11-12 4 S $81.51 $81,513 D/D (1,000) 228,157 2%     
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2014-11-10 4 OE $12.99 $51,960 I/I 4,000 47,195     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2014-11-10 4 S $87.00 $348,000 I/I (4,000) 43,195 2%     
   Fuchs Henry J EVP, Chief Medical Officer   •       –      –    2014-11-10 4 OE $21.51 $430,200 D/D 20,000 96,550     -
   Fuchs Henry J EVP, Chief Medical Officer   •       –      –    2014-11-10 4 S $86.55 $1,730,982 D/D (20,000) 76,550 2%     
   Ajer Jeffrey Robert SVP, Chief Commercial Of   •       –      –    2014-11-03 4 AS $83.54 $3,926 D/D (47) 31,590 4%     
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2014-11-03 4 S $85.33 $256,002 I/I (3,000) 43,195 -4%     
   Ajer Jeffrey Robert SVP, Chief Commercial Of   •       –      –    2014-10-31 4 A $31.26 $1,469 D/D 47 31,637     -
   Baffi Robert EVP, Technical Operations   •       –      –    2014-10-30 4 OE $38.59 $1,156,272 D/D 29,963 129,163     -
   Baffi Robert EVP, Technical Operations   •       –      –    2014-10-30 4 S $81.70 $2,447,959 D/D (29,963) 99,200 -6%     
   Davis George Eric SVP, General Counsel   •       –      –    2014-10-30 4 OE $26.49 $397,350 D/D 15,000 79,426     -
   Davis George Eric SVP, General Counsel   •       –      –    2014-10-30 4 S $83.20 $1,247,930 D/D (15,000) 64,426 -6%     
   Baffi Robert EVP, Technical Operations   •       –      –    2014-10-29 4 OE $17.33 $1,533,721 D/D 45,462 144,662     -
   Baffi Robert EVP, Technical Operations   •       –      –    2014-10-29 4 S $81.10 $3,686,955 D/D (45,462) 99,200 -6%     
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2014-10-24 4 OE $12.99 $25,980 I/I 2,000 48,195     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2014-10-24 4 AS $80.00 $160,000 I/I (2,000) 46,195 4%     
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2014-10-21 4 OE $12.99 $25,980 I/I 2,000 48,195     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2014-10-21 4 AS $75.00 $150,000 I/I (2,000) 46,195 20%     
   Davis George Eric SVP, General Counsel   •       –      –    2014-09-19 4 OE $21.51 $377,199 D/D 17,536 81,962     -
   Davis George Eric SVP, General Counsel   •       –      –    2014-09-19 4 AS $69.75 $1,223,136 D/D (17,536) 64,426 22%     
   Spiegelman Daniel K EVP, Chief Financial Officer   •       –      –    2014-09-02 4 OE $39.06 $624,960 D/D 16,000 84,676     -
   Spiegelman Daniel K EVP, Chief Financial Officer   •       –      –    2014-09-02 4 S $69.83 $1,117,314 D/D (16,000) 68,676 -21%     
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2014-08-20 4 OE $12.99 $64,950 I/I 5,000 51,195     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2014-08-20 4 AS $70.00 $350,000 I/I (5,000) 46,195 21%     
   Fuchs Henry J EVP, Chief Medical Officer   •       –      –    2014-08-05 4 OE $21.51 $215,100 D/D 10,000 86,550     -

  1276 Records found
  1  2  3  4  5  6  7  8  9  Next   
  Page 1 of 52
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed